En el vasto mundo microscópico, existe un grupo de criaturas que desafían las expectativas de los científicos: los tardígrados. Estos diminutos organismos, conocidos cariñosamente como “osos de agua”, no solo son extraordinariamente resistentes, sino que …
Essential Pharma announces that it has completed the acquisition of European rights to Colobreathe® from Teva Laboratories UK Limited.
Occlutech Holding AG Occlutech ASD Occluder delivers positive procedural outcomes with strong efficacy and a low rate of complications.
Accelerate Diagnostics, Inc. announced certain preliminary, unaudited results for the quarter and year ended December 31, 2023.
Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2023.
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results Read More »
Orion Corporation and Glykos Finland Oy announced that they have entered into a research collaboration and licensing agreement to develop next-generation antibody-drug conjugates.
Calliditas Therapeutics AB, a commercial biopharma company focused on rare diseases provided a business update for the fourth quarter of 2023 and certain preliminary, unaudited key financial information for the fourth quarter and full year 2023, as follows.
Calliditas Therapeutics provides business update ahead of JP Morgan conference Read More »
Guardant Health, Inc. and Hikma Pharmaceuticals PLC announced an agreement to promote Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling across all solid cancers in countries across the Middle East and North Africa.
Caliway Biopharmaceuticals announced that the United States Food and Drug Administration has accepted the CBL-514 Investigational New Drug application of CBL-0202 DD Phase 2 Study to treat Dercum’s Disease.
MorphoSys AG announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PST in San Francisco, California.
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference Read More »
